Regeneron Pharmaceuticals agreed to purchase 23andMe for $256 million in a bankruptcy court auction, the company said Monday. The move allows 23andMe to continue to provide DNA testing services ...

Regeneron Pharmaceuticals announced on Monday that it will acquire "substantially all" of genetic testing company 23andMe's assets. The pharmaceutical company said it won the court-supervised ...

She regularly appears on CBS News 24/7 to discuss her reporting. Regeneron has agreed to buy 23andMe, the once buzzy genetic testing company, out of bankruptcy for $256 million under a court ...

23andMe has found itself a buyer after biotech Regeneron won an auction to buy the bankrupt genetics company for $256m. As part of a court-supervised sale, the auction will see Regeneron acquire ...

Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe for $256 million through a bankruptcy auction, the companies said Monday. Regeneron said it will comply with 23andMe’s ...

Tarrytown-based Regeneron would acquire 23andMe for $256 million under the deal that is pending approval by bankruptcy court and regulators. New York-based biotech giant Regeneron Pharmaceuticals ...

The US biotech company Regeneron has agreed to buy 23andMe and all of its assets for $256 million (even though it was valued at $50 million in March). This purchase marks the end of former 23andMe ...

Regeneron Pharmaceuticals, a biotechnology company with a long history of large-scale genetics research, plans to buy DNA testing firm 23andMe out of bankruptcy, announcing Monday it was named the ...

Amgen prevented Regeneron from competing on a level playing field and unfairly denied patients access to Praluent. This anticompetitive practice shut out an innovative therapy from the PCSK9 ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era. But even as the billions pile up, Regeneron isn't entirely happy with ...

Regeneron Pharmaceuticals, Inc.'s stock has dropped 30% since July due to concerns around Eylea's declining market share in the face of competition from generics and Roche's Vabysmo. Dupixent's ...